impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

High CD14+ peripheral monocytes expression of ALX/FPR2 and BLT1 in low disease activity and remission status in rheumatoid arthritis: a piltot study

1, 2, 3, 4, 5, 6

 

  1. Rheumatology Unit, Department of Emergence Medicine and Transplantation (DETO), University of Bari “Aldo Moro”, Bari, and Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. perniolasi@hotmail.it
  2. Rheumatology Unit, Department of Emergence Medicine and Transplantation (DETO), University of Bari “Aldo Moro”, Bari, Italy.
  3. Rheumatology Unit, Department of Emergence Medicine and Transplantation (DETO), University of Bari “Aldo Moro”, Bari, Italy.
  4. Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, and Institute of Rheumatology, Università Cattolica del Sacro Cuore, Rome, Italy.
  5. Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, and Institute of Rheumatology, Università Cattolica del Sacro Cuore, Rome, Italy.
  6. Rheumatology Unit, Department of Emergence Medicine and Transplantation (DETO), University of Bari “Aldo Moro”, Bari, Italy.

CER14458
2022 Vol.40, N°5
PI 1019, PF 1024
Full Papers

purchase article

PMID: 34494955 [PubMed]

Received: 24/01/2021
Accepted : 10/05/2021
In Press: 07/09/2021
Published: 13/05/2022

Abstract

OBJECTIVES:
Specialised pro-resolving mediator (SPM) can dampen the acute inflammation through ERV1, ALX/FPR2 and BLT1 cell receptors and it is conceivable that their expression is dysregulated during chronic inflammation. The aim of this study was to evaluate the expression of ERV1, ALX/FPR2 and BLT1 on peripheral blood (PB) cells from rheumatoid arthritis (RA) patients.
METHODS:
At baseline, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), clinimetric indexes (28-joint disease activity score (DAS28) and clinical disease activity index (CDAI)), and PB samples were collected from 33 RA patients. Based on DAS28, patients were divided into high-moderate (H-Mo/RA, DAS28≥3.2) and low-remission (L-Rem/RA, DAS28<3.2) disease activity group. Cell membrane expression of ERV1, ALX/FPR2 and BLT1 on CD3pos, CD19pos, CD14pos cells and granulocytes was assessed by multi-parametric flow-cytometry analysis. Nine healthy controls (HC) were also studied.
RESULTS:
Sixteen H-Mo/RA and 17 L-Rem/RA patients were identified. The percentage of BLT1posCD14pos cells was significantly higher in L-Rem/RA (47.17%) than in H-Mo/RA (14.27%) group (p=0.005). Likewise, the percentage ALX/FPR2pos CD14pos cells was significantly higher in L-Rem/RA (33.02%) than in H-Mo/RA (8.77%; p=0.04) patients. An inverse correlation between BLT1posCD14pos cell percentage and DAS28 (r=-0.42; p=0.01), CDAI (r=-0.51; p=0.003), ESR (r=-0.39; p=0.025) and CRP (r=-0.40; p=0.02), ALX/FPR2posCD14pos cell percentage and CRP (r=-0.39; p=0.02) were found, while SPM-receptors mean fluorescence intensity (MFI) was not different between HC and L-Rem/RA patients.
CONCLUSIONS:
ALX/FPR2 and BLT1 receptors expression mirrors RA disease activity arising as potential biomarkers of inflammatory regulation.

DOI: https://doi.org/10.55563/clinexprheumatol/akl60y

Rheumatology Article

Rheumatology Addendum